Ahuja Rahul, Vishwakarma Preeti, Kumar Varun, Khatri Ritika, Chatterjee Ananya, Mishra Surbhi, Rizvi Zaigham Abbas, Singh Anup, Kaur Gurleen, Maithil Vikas, Tarane Kunal, Chauhan Akanksha, Singh Sarjeet, Yadav Pooja, Yadav Devendra, Sinha Sangita Kumari, Ali Syed Khalid, Chatterjee Abhisek, Priyadarsiny Priyanka, Awasthi Amit, Prasad Vidya Mangala, Ahmed Shubbir, Samal Sweety
Centre for Virus Research, Therapeutics and Vaccines, Translational Health Science & Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Molecular Biophysics Unit, Indian Institute of Science, Bangalore, Karnataka, India.
NPJ Vaccines. 2025 Jun 6;10(1):117. doi: 10.1038/s41541-025-01174-1.
The recent emergence and global spread of the human Monkeypox virus (MPXV), including its transmission to non-endemic regions, have raised significant global health concerns. In this proof-of-concept study, we developed a recombinant protein-based MPXV vaccine candidate, employing an innovative and versatile multivalent, self-assembled nanocage protein scaffold. Two immunogenic antigens derived from the contemporary circulating MPXV strain have been incorporated into a self-assembled non-structural protein-10 (NSP-10) scaffold, expressed, and purified using an Escherichia coli expression system without a purification tag. The vaccine candidate elicited strong antibody responses in mice and conferred protection against the lethal Vaccinia virus in an intranasal and skin pock in vivo study. Additionally, an intranasal challenge with the MPXV strain clade IIb in immunized mice demonstrated promising outcomes, including a significant reduction in viral titres and eliciting a robust neutralizing antibody response. This study demonstrates a feasible, scalable, and cost-effective approach for the development of the MPXV vaccine.
人类猴痘病毒（MPXV）最近的出现和全球传播，包括其向非流行地区的传播，引发了重大的全球健康担忧。在这项概念验证研究中，我们开发了一种基于重组蛋白的MPXV候选疫苗，采用了一种创新且通用的多价自组装纳米笼蛋白支架。源自当代流行MPXV毒株的两种免疫原性抗原已被整合到一个自组装的非结构蛋白10（NSP-10）支架中，使用无纯化标签的大肠杆菌表达系统进行表达和纯化。该候选疫苗在小鼠中引发了强烈的抗体反应，并在一项鼻内和皮肤痘疤的体内研究中对致死性痘苗病毒提供了保护。此外，在免疫小鼠中用MPXV IIb分支毒株进行鼻内攻击显示出了有前景的结果，包括病毒滴度显著降低以及引发强烈的中和抗体反应。这项研究展示了一种开发MPXV疫苗的可行、可扩展且具有成本效益的方法。
